COVID-19 in clinical practice: A narrative synthesis

M. Le Maréchal , P. Morand , O. Epaulard , B. Némoz
{"title":"COVID-19 in clinical practice: A narrative synthesis","authors":"M. Le Maréchal ,&nbsp;P. Morand ,&nbsp;O. Epaulard ,&nbsp;B. Némoz","doi":"10.1016/j.medmal.2020.09.012","DOIUrl":null,"url":null,"abstract":"<div><p>The coronavirus disease 2019 (COVID-19) was first reported in the city of Wuhan, China. The disease rapidly spread to the rest of China, to Southern-East Asia, then to Europe, America, and on to the rest of the world. COVID-19 is associated with a betacoronavirus named SARS-CoV-2. The virus penetrates the organism through the respiratory tract, conveyed by contaminated droplets. The main cell receptor targeted is the surface-bound ACE-2. As of the 26th July 2020, 15,200,000 COVID-19 cases and 650,000 deaths were reported worldwide. The mortality rate is estimated between 1.3 and 18.3%. The reproductive rate without any public health intervention is estimated around 4-5.1 in France. Most hospitalized patients for COVID-19 present respiratory symptoms, which in some cases is associated with fever. Up to 86% of admissions to ICU are related to acute respiratory failure. To date, no anti-viral therapy has proven its efficacy considering randomized trials. Only immunomodulatory treatments such as corticosteroids have shown to cause significant improvement in patient outcome.</p></div>","PeriodicalId":18464,"journal":{"name":"Medecine et maladies infectieuses","volume":null,"pages":null},"PeriodicalIF":5.0000,"publicationDate":"2020-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.medmal.2020.09.012","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medecine et maladies infectieuses","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0399077X20307101","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 2

Abstract

The coronavirus disease 2019 (COVID-19) was first reported in the city of Wuhan, China. The disease rapidly spread to the rest of China, to Southern-East Asia, then to Europe, America, and on to the rest of the world. COVID-19 is associated with a betacoronavirus named SARS-CoV-2. The virus penetrates the organism through the respiratory tract, conveyed by contaminated droplets. The main cell receptor targeted is the surface-bound ACE-2. As of the 26th July 2020, 15,200,000 COVID-19 cases and 650,000 deaths were reported worldwide. The mortality rate is estimated between 1.3 and 18.3%. The reproductive rate without any public health intervention is estimated around 4-5.1 in France. Most hospitalized patients for COVID-19 present respiratory symptoms, which in some cases is associated with fever. Up to 86% of admissions to ICU are related to acute respiratory failure. To date, no anti-viral therapy has proven its efficacy considering randomized trials. Only immunomodulatory treatments such as corticosteroids have shown to cause significant improvement in patient outcome.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
临床实践中的COVID-19:叙事综合
2019冠状病毒病(COVID-19)首先在中国武汉市报告。这种疾病迅速蔓延到中国其他地区、东南亚、欧洲、美洲和世界其他地区。COVID-19与一种名为SARS-CoV-2的冠状病毒有关。病毒通过呼吸道通过被污染的飞沫传播。主要靶向的细胞受体是表面结合的ACE-2。截至2020年7月26日,全球共报告了1520万例COVID-19病例和65万例死亡。死亡率估计在1.3%至18.3%之间。在没有任何公共卫生干预的情况下,法国的生殖率估计约为4.5.1。大多数因COVID-19住院的患者都出现呼吸道症状,在某些情况下还伴有发烧。高达86%的ICU入院与急性呼吸衰竭有关。迄今为止,考虑到随机试验,尚无抗病毒疗法证明其疗效。只有免疫调节治疗,如皮质类固醇,已显示对患者预后有显著改善。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Medecine et maladies infectieuses
Medecine et maladies infectieuses 医学-传染病学
CiteScore
1.10
自引率
0.00%
发文量
0
审稿时长
10.7 weeks
期刊介绍: L''organe d''expression de la Société de Pathologie Infectieuse de Langue Française (SPILF). Médecine et Maladies Infectieuses is the official publication of the Société de Pathologie Infectieuse de Langue Française (SPILF). Médecine et Maladies Infectieuses is indexed in the major databases: Medline, Web of Science/Clarivate and Scopus. The journal publishes scientific /research articles, general reviews, short communications and letters, in both English and French. The journal welcomes submissions on the various aspects of infectious pathologies and pathogenic agents. Médecine et Maladies Infectieuses focuses on clinical therapeutics, nosocomial infections, biology, prevention, as well as epidemiology and therapeutics.
期刊最新文献
Editorial board Implant retention and high rate of treatment failure in hematogenous acute knee and hip prosthetic joint infections PK/PD targets of amikacin and gentamicin in ICU patients Flu vaccine coverage for recommended populations in France Antimicrobial resistance in N’Djamena (Chad): Four-year experience of the French Forward Medical and Surgical Team engaged in the “Barkhane Operation”
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1